A l'oeil malade la lumiere nuit.

摘要

In this issue, Marshall et al. (pages 2319-2323) present clinical results of a current-generation blue-light-filtering intraocular lens (IOL). Not surprisingly, they demonstrate that in the optical sense, the IOL functions the same as its nonfiltering counterpart, but they note "[additional long-term studies should be able to show whether the lens actually provides the theoretical benefits to retinal health."Perhaps it is too simplistic to believe that the multifactorial problem of macular degeneration can be ameliorated by the simple expedient of blocking ultraviolet (UV) and blue-light transmission to the retina by incorporating a filtering mechanism in the replacement implant for the crystalline lens. The literature on the contribution of UV and blue light to the degeneration of the macula through deleterious effects on the central retinal pigment epithelium (RPE) and photoreceptors is equivocal, as may be expected when molecular biology, optics, physics are some of the elements that need comprehension. Clinical case-control studies may require lifetimes to be effective and are not sustainable in the practical sense.